Global Peptide Therapeutics Markets, 2021-2026 - Increase Bioavailability of Drugs and Broaden Application of Peptides Therapeutics - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Peptide Therapeutics Market (2021 Edition) - Analysis By Drug Type (Generic, Innovative), Manufacturing Type (In-House, Outsourced), Application, By Region, By Country: Market Insights, Covid-19 Impact, Competition and Forecast (2021-2026)" report has been added to ResearchAndMarkets.com's offering.

The Global Peptide Therapeutics Market is valued at USD 32.1 Billion in the year 2020.

The factors such as surging prevalence of cancer, rising healthcare expenditure, growing incidence of metabolic disorders, increasing geriatric population and accelerating number of approved peptide-based therapeutic drugs.

New drug discovery and product launch in chronic metabolic disorders expected to provide potential opportunities to Peptide Therapeutics Market, further supported by factors such as surging prevalence of cancer, rising healthcare expenditure, growing incidence of metabolic disorders, increasing geriatric population and accelerating number of approved peptide-based therapeutic drugs.

Over the years, the rising popularity of biologics, such as peptide therapeutics, have led to an evident shift in the focus of the healthcare industry, from traditional small molecule-based interventions to upcoming, albeit complex, family of pharmacological interventions.

The success of peptide therapeutics, so far, can be attributed to their clinical benefits, which include high target specificity, low toxicity and favorable safety profiles. Furthermore, with enhanced technologies, the prospects of the peptide drugs are getting influential day by day and new peptides are being discovered to be developed as peptide drug.

Peptide therapeutics is completely different from the traditional way and may open a new window for finding completely new peptide drugs.

Moreover, Peptide gives an opportunity for therapeutics intervention that follows natural pathways hence there has been decline in non-peptide chemically synthesized drug discovery as well as rise in peptide generic market and collaboration of pharmaceutical companies with biotechnology fueling the market growth of peptide therapeutics.

The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Novartis, Sanofi, Pfizer, GlaxoSmithKline, Eli Lilly and Company, AstraZeneca Plc., Novo Nordisk, Amgen Inc., Takeda Pharmaceutical Company Limited, Bristol-Mayer Squibb.

Key Topics Covered:

1. Report Scope and Methodology

2. Strategic Recommendations

2.1 Increase bioavailability of drugs and broaden application of peptides therapeutic

2.2 Asia Pacific region to witness augmented growth in the forecast period

3. Peptides Therapeutic Market: Product Outlook

4. Global Peptides Therapeutic Market: Sizing and Forecast

4.1 Global Peptides Therapeutic Market Size, By Value, Year 2016-2026

5. Global Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type

5.1 Competitive Scenario of Global Peptides Therapeutic Market: By Application

5.1.1 Metabolic - Market Size and Forecast (2016-2026)

5.1.2 Oncology - Market Size and Forecast (2016-2026)

5.1.3 Gastrointestinal - Market Size and Forecast (2016-2026)

5.1.4 Cardiovascular - Market Size and Forecast (2016-2026)

5.1.5 Neurological - Market Size and Forecast (2016-2026)

5.1.6 Others - Market Size and Forecast (2016-2026)

5.2 Competitive Scenario of Global Peptides Therapeutic Market: By Drug Type

5.2.1 Generic - Market Size and Forecast (2016-2026)

5.2.2 Innovative- Market Size and Forecast (2016-2026)

5.3 Competitive Scenario of Global Peptides Therapeutic Market: By Manufacturing Type

5.3.1 In-house - Market Size and Forecast (2016-2026)

5.3.2 Outsourced - Market Size and Forecast (2016-2026)

6. Global Peptides Therapeutic Market: Regional Analysis

6.1 Competitive Scenario of Global Peptides Therapeutic Market: By Region

7. North America Peptides Therapeutic Market: An Analysis (2016-2026)

7.1 North America Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value

7.2 North America Peptides Therapeutic Market - Prominent Companies

7.3 Market Segmentation By Application (Metabolic, Oncology, Gastrointestinal, Cardiovascular, Neurological and Others)

7.4 Market Segmentation By Drug Type (Generic, Innovative)

7.5 Market Segmentation By Manufacturing Type (In-house, Outsourced)

7.6 North America Peptides Therapeutic Market: Country Analysis

7.7 Market Opportunity Chart of North America Peptides Therapeutic Market - By Country, By Value, 2026

7.8 Competitive Scenario of North America Peptides Therapeutic Market: By Country

7.9 United States Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value

7.10 United States Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)

7.11 Canada Peptides Therapeutic Market: Size and Forecast (2016-2026), By Value

7.12 Canada Peptides Therapeutic Market Segmentation - By Application, By Drug Type, By Manufacturing Type (2016-2026)

8. Europe Peptides Therapeutic Market: An Analysis (2016-2026)

9. Asia Pacific Peptides Therapeutic Market: An Analysis (2016-2026)

10. Global Peptides Therapeutic Market Dynamics

10.1 Drivers

10.2 Restraints

10.3 Trends

11. Market Attractiveness

11.1 Market Attractiveness Chart of Global Peptides Therapeutic Market - By Application, 2026

11.2 Market Attractiveness Chart of Global Peptides Therapeutic Market - By drug Type, 2026

11.3 Market Attractiveness Chart of Global Peptides Therapeutic Market - By Manufacturing Type, 2026

11.4 Market Attractiveness Chart of Global Peptides Therapeutic Market - By Region, 2026

12. Competitive Landscape

12.1 Major Technological Innovations, Mergers & Acquisitions and Role of Manufacturers

12.2 Market Share Analysis

13. Company Analysis

13.1 Novartis

13.2 Sanofi

13.3 Pfizer

13.4 GlaxoSmithKline

13.5 Eli Lilly and Company

13.6 AstraZeneca Plc

13.7 Novo Nordisk

13.8 Amgen Inc

13.9 Takeda Pharmaceutical Company Limited

13.10 Bristol-Mayer Squibb

For more information about this report visit https://www.researchandmarkets.com/r/bqs1bu

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900